Mercado Global de Tratamento de Porfiria Hepática Aguda – Tendências do setor e previsão para 2030

 Análise e dimensão do mercado de tratamento da porfiria hepática aguda

De acordo com o NCBI, prevê-se que a ocorrência global de porfiria hepática aguda varie de um em 500 a um em 50.000 indivíduos. A porfiria hepática aguda (AHP) é um dos tipos de porfiria hepática. A incidência de porfiria hepática aguda clínica está estimada em cerca de 5 a 10 por 100.000 indivíduos. É testemunhado o aumento persistente de bolsas de investigação e despesas em I&D por parte do governo e de outras empresas farmacêuticas para impulsionar o desenvolvimento de medicamentos para doenças raras que mudariam o cenário do tratamento das porfirias.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado de tratamento da porfiria hepática aguda no período de previsão 2023-2030. O CAGR esperado do mercado de tratamento da porfiria hepática aguda tende a rondar os 5% no período de previsão mencionado. O mercado foi avaliado em 3,72 milhões de dólares em 2022 e cresceria até 5,5 milhões de dólares até 2030. Para além dos insights de mercado, como o valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes no mercado e cenário de mercado, o mercado O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de tratamento da porfiria hepática aguda

Market Definition

Acute hepatic porphyria is a group of inherited diseases that are genetically different in nature; thoough, they are caused because of overproduction of heme precursors. The clinical symptoms include chest pain, vomiting, muscles pain, nausea, weakness and others. Porphyrias treatment may include evading the triggers, consumption of medicines to relieve symptoms, receiving heme through a vein, or sometimes having blood drawn to decrease iron in the body. Currently, there is no proper cure for this condition

Acute Hepatic Porphyria Treatment Market Dynamics

Drivers

• Growing Demands of Diagnostic Tests

There are numerous diagnostic tests that are boosting the demand of the market. Genetic testing is the primary standard test for diagnosing this condition. A genetic test can check if the person has one gene mutation that can cause AHP. It can also tell what type of AHP the patient have and how serious the enzyme deficiency is. A genetic test uses a sample of your blood or saliva. Thus, it increases the demand of the treatment drugs.  

• Growing Incidences Of Acute Hepatic Porphyria

As per the records of NCBI, the global incidence of acute hepatic porphyria is estimated to range from one in 500 to one in 50,000 individuals. In most of the regions, acute intermittent porphyria (AIP) is the most common, and ALA dehydratase-deficiency porphyria (ALAD) is the least common. The incidence of clinical AIP is witnessed to be around 5 to 10 per 100,000 individuals, and the incidence of genetic mutations of AIP is around one in 1675 individuals. This high rate of incidence is likely to drive the demand for the market.

Opportunities

•  Growing Demand of Diverse Treatment Methods

There are several treatment methods that are aiding in boosting the growth of the market. Panhematin is the only commercially available heme therapy in the U.S. for this condition. People suffering from severe porphyric attacks are treated with heme given by vein. If porphyrias treatment is postponed, then recovery takes longer and nerve damage may be long-lasting. Additionally, a high carbohydrate diet and intravenous glucose therapy for mild attacks are generally advised for porphyrias treatment. Liver transplantation is suggested for acute intermittent porphyria.

 Restraints/Challenges

• Discontinuation of Drug Trials

The drug development for the disease has faced foremost obstacles as numerous therapies have failed to reveal efficacy or were associated with major toxicity. Therefore, this hampers the growth of the market.

This acute hepatic porphyria treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute hepatic porphyria treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Acute Hepatic Porphyria Treatment Market Scope

The acute hepatic porphyria treatment market is segmented on the basis of treatment, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Acute Intermittent Porphyria (AIP)
• Hereditary Coproporphyria (HCP)
• Others

Treatment

• Medications
• Caloric Deprivation
• Dehydration
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Acute Hepatic Porphyria Treatment Market Regional Analysis/Insights

The acute hepatic porphyria treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the acute hepatic porphyria treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific will be expecting positive growth for acute hepatic porphyria treatment market throughout the forecasted period due to growing awareness among the population and increase in patient population.

A América do Norte domina o mercado devido a políticas de reembolso bem definidas de diversas empresas de seguros de saúde públicas e privadas que ajudam a proporcionar aos doentes um fácil acesso ao diagnóstico e a amplas atividades de I&D. Nos EUA, cerca de 5.000 pessoas sofrem anualmente um ou mais ataques agudos de porfiria hepática.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Cenário competitivo e análise global da quota de mercado do tratamento da porfiria hepática aguda

O panorama competitivo do mercado de tratamento da porfiria hepática aguda fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de tratamento da porfiria hepática aguda.

Os principais players que trabalham no mercado Tratamento da porfiria hepática aguda incluem:

• Teva Pharmaceutical Industries Ltd (Israel)
• Apotex Inc (Canadá)
• Pfizer Inc (EUA)
• H. Lundbeck A/S (Dinamarca)
• Lily (EUA)
• F. Hoffmann-La Roche Ltd. (Suíça)
• Mylan NV (EUA)
• Siemens Healthcare GmbH (Alemanha)
• (EUA)
• Danaher. (NÓS)
• ARKRAY, Inc (Japão)
• Abbott (EUA)
• Alnylam Pharmaceuticals, Inc (EUA)
• Corporação Científica de Boston (EUA)
• (EUA)
• Recordati Rare Diseases Inc (Itália)

SKU-59236